ImmuneSpec

Skip to content

CHECKED

Companies Insolvencies Sectors Watchlist Alerts API

Sign in

ImmuneSpec

Niel ·KBO/BCE: BE 0797.707.610

Loading dossier…

Checked · Insight, alerts and connections for every Belgian company, from official sources.

NL FR EN

Product

Search companies Sectors Radar Live Compare Prospects Supplier check Feasibility Decision tools Company map

Data & registers

Insolvencies Curators Directors Director bans Protection orders Notaries News

Account

Watchlist Portfolio Alerts Pricing

Checked

About Methodology Knowledge base Sources FAQ Help API Developers Badge Business information compared Free company information

Legal

Privacy Terms Contact

Checked AI

Open a company dossier to ask Checked AI about it.

Your question travels, with the dossier's public data, to our AI model at Anthropic in the US. Nothing that identifies you goes along, and we keep neither question nor answer. Answers can be wrong, so this is not legal advice. How it works

Metric	This company	Sector median	Position in the sector
Solvency	74.6%	49.8%	better than 69% of 81 sector peers
Net result	€-202k	€17k	better than 16% of 80 sector peers
Equity	€2.64M	€102k	better than 90% of 81 sector peers
Gross operating margin	€884k	€49k	better than 95% of 76 sector peers
Total assets	€3.54M	€250k	better than 87% of 81 sector peers

Fiscal year	2025
Revenue	-
EBITDA	€506k
Net profit	€-202k
Cash flow	€482k
Staff costs	€376k
Income taxes	€-12k
Dividends	-
Total assets	€3.54M
Equity	€2.64M
Debt	€897k
of which ≤ 1y	€444k
of which > 1y	€385k
Working capital	€991k
Employees (FTE)	5.7

	2025
Current ratio	3.23
Quick ratio	3.23
Working capital ratio	28.0%
Solvency	74.6%
Debt / equity	0.34
Long-term debt ratio	0.15
Interest coverage	13.01
Gross margin	-
Net margin	-
ROA	-5.7%
ROE	-7.6%
EBITDA margin	-
Days sales outstanding	-
Days payable outstanding	-
Inventory turnover	-
Days inventory (DSI)	-

Line item	Code	2025
Balance sheet, Assets
TOTAL ASSETS	20/58	€3.54M
Fixed assets	21/28	€2.10M
Intangible fixed assets	21	€1.10M
Tangible fixed assets	22/27	€975k
Financial fixed assets	28	€26k
Current assets	29/58	€1.44M
Amounts receivable within one year	40/41	€689k
Investments	50/53	€450k
Cash & bank	54/58	€192k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€3.54M
Equity	10/15	€2.64M
Contributions / capital	10/11	€3.32M
Accumulated profits (losses)	14	€-677k
Amounts payable	17/49	€897k
Amounts payable after one year	17	€385k
Amounts payable within one year	42/48	€444k
Trade debts payable within one year	44	€143k
Income statement
Gross operating margin	9900	€884k
Operating result	9901	€-178k
Financial income	75	€3k
Financial charges	65	€39k
Result before taxes	9903	€-214k
Income taxes	67/77	€-12k
Net result for the period	9904	€-202k
Result to be appropriated	9905	€-202k

NACE primary	Speur- en ontwikkelingswerk op biotechnologisch gebied(72101)
Legal form	Private limited company(610)
Incorporation	27-01-2023
Status	Active
Postal code	2845

Summary

Conclusion

Trust signals

Administrative Flags

Bankruptcy probability (12 mo)

Financials

Annual accounts & ratios

Health barometer

Directors

Directors & mandates

Insolvency mandates

Legal Structure

Structure & network

Connections & network

Locations & real estate

Registered office

Establishment units

Real-estate footprint

Publications

Lifecycle & Insolvency Signals

Belgisch Staatsblad · acts

Analysis

Snowflake analysis

Ask AI about this company

AI due-diligence brief

Credit advice

Similar

Similar companies

Company registry

Company registry (CBE)